PAUL H PEVSNER
Medical Practice in New York, NY

7714276, May 11, 2010

Sep 29, 2006

11/541380

Paul Pevsner - New York NY, US
Frederick Naftolin - Woodbridge CT, US
Douglas C. Miller - Delle Mead NJ, US
Dean Hillman - New Hyde Park NY, US
Brian K. Stall - Bedford NH, US
Steven M. Wishnie - Columbia MD, US

New York University - New York NY

B01D 59/44

250282, 250287

The present invention relates to the use of post source decay (PSD) or collision induced dissociation (CID) direct tissue (DT) MALDI-TOF or DT-MALDI-TOF-TOF mass spectrographic identification of biological molecules in a tissue or cellular sample without the need for further protein extraction. This method provides for studying cells or tissues by direct tissue MALDI (DT-MALDI), thereby substituting in situ protein release for further protein extraction. Mass/intensity data was processed with Mascot© software interrogation of the NCBI database. These results are proof of principle that DT-MALDI, combined with bioinformatics, can directly identify proteins in cells and tissues from their mass spectra.

8269163, Sep 18, 2012

May 4, 2009

12/387508

Paul H. Pevsner - New York NY, US

New York University - New York NY

B01D 59/44, H01J 49/00

250282, 250281, 250287, 250288, 435 6, 435 7, 43510821, 435194

The present invention provides novel radiation associated markers. The radiation associated markers may be one or more of albumin, LTGF-β, or any protein or peptide listed in any one of Tables 1, 2, 3, 4, 5, and 6 provided herein. The present invention also provides methods of assessing exposure to ionizing radiation by determining the presence of one or more radiation associated markers. The methods may optionally include quantifying one or more of the radiation associated markers. The methods may further include comparing the amount of one or more radiation associated markers in the sample determined to be present in the sample with either (i) the amount determined for temporally matched, normal samples or (ii) the amount determined for samples obtained from individuals or subjects that have not been exposed to an elevated level of ionizing radiation. The present invention further provides a method of predicting outcome in a subject after exposure to elevated levels of ionizing radiation. Further, the present invention provides a method of determining the amount of radiation therapy that has been delivered to a particular tissue.

8525104, Sep 3, 2013

Apr 27, 2010

12/799576

Paul Pevsner - New York NY, US
Frederick Naftolin - Woodbridge CT, US
Douglas C. Miller - Belle Mead NJ, US
Dean Hillman - New Hyde Park NY, US
Brian K. Stall - Bedford NH, US
Steven M. Wishnies - Columbia MD, US

New York University - New York NY

B01D 59/44, H01J 49/00, H01J 49/40

250281, 250288, 250282

The present invention relates to the use of post source decay (PSD) or collision induced dissociation (CID) direct tissue (DT) MALDI-TOF or DT-MALDI-TOF-TOF mass spectrographic identification of biological molecules in a tissue or cellular sample without the need for further protein extraction. This method provides for studying cells or tissues by direct tissue MALDI (DT-MALDI), thereby substituting in situ protein release for further protein extraction. Mass/intensity data was processed with Mascot© software interrogation of the NCBI database. These results are proof of principle that DT-MALDI, combined with bioinformatics, can directly identify proteins in cells and tissues from their mass spectra.

2009007, Mar 19, 2009

Sep 5, 2008

12/231894

Paul H. Pevsner - New York NY, US
Frederick Naftolin - New York NY, US
Jamie Grifo - New York NY, US
Fred Licciardi - New York NY, US

G01N 33/53, C12Q 1/02

435 71, 435 29

The present invention provides methods for predicting the viability of an embryo or for predicting the likelihood of a negative outcome during pregnancy by identifying the presence or absence of or determining the amount of one or more pregnancy associated markers such as molecular isoforms of hCG in a sample. In many instances, the invention is applicable to embryos generated by in vitro fertilization techniques, for instance, to embryos developing in a growth media. The present invention further provides methods for determining the amount of a pregnancy associated markers such as molecular isoforms of hCG (hCG) in a sample. The present invention also provides a diagnostic kit for predicting the viability of an embryo or for predicting the likelihood of a negative outcome during pregnancy by identifying the presence of or determining the amount of one or more pregnancy associated markers such as molecular isoforms of hCG in a sample.

2007011, May 17, 2007

Sep 28, 2006

11/541403

Paul Pevsner - New York NY, US
Frederick Naftolin - Woodbridge CT, US
Ahmed Metwaly - New Haven CT, US
Erol Gulcicek - Madison CT, US

A61K 51/00, A01N 1/02, A61K 49/04, C12Q 1/00

424001110, 424009400, 435001100, 435004000

A minimally invasive procedure for perfusion-impregnation of tissues, organs and cells is provided that aids in the retention of tissue and cellular architecture without the formation of artifacts. The procedure allows for monitoring drug disposition, for detecting diseased tissue and for monitoring the presence of target molecules in a sample using various imaging techniques, including matrix assisted laser desorption ionization mass spectrometry (MALDI-MS).

2009017, Jul 2, 2009

Dec 11, 2008

12/316374

Paul H. Pevsner - New York NY, US

G01N 33/574, G01N 33/68, G01N 33/72, C12Q 1/32, G01N 33/566

435 723, 436 86, 436 66, 435 26, 436501

The present invention provides methods for diagnosing carcinoma, providing a prognosis for a carcinoma or assessing the likelihood that a tissue may become cancerous by identifying the presence or absence of or determining the amount of one or more carcinoma associated markers. Further, the present invention provides methods for determining whether a tissue should be surgically resected and for determining the territorial extent of resection. The carcinoma markers may be those provided in FIG. The present invention also provides a diagnostic kit for diagnosing carcinoma, providing a prognosis for a carcinoma or assessing the likelihood that a tissue may become cancerous by identifying the presence of or determining the amount of one or more carcinoma associated markers. The methods and kits are especially useful regarding colon, rectal or colorectal carcinoma.

2013000, Jan 3, 2013

Jan 3, 2012

13/342823

John David Robertson - Columbia MO, US
Mark F. McLaughlin - Columbia MO, US
Paul H. Pevsner - New York NY, US

THE CURATORS OF THE UNIVERSITY OF MISSOURI - Columbia MO

A61K 51/12, A61P 35/00, B05D 5/00, B82Y 5/00, B82Y 40/00

424 129, 427 214, 977773, 977890, 977915

The present invention is directed α-particle emitting nanoparticles that comprise a lanthanide phosphate sequestration shell enclosing an α-emitting-radioisotope-doped lanthanide phosphate core such that the shell allows at least some of the α emissions from the α-emitting radioisotope to pass therethrough and prevents at least some radioactive decay products of the α-emitting radioisotope from exiting the α-particle emitting nanoparticle. Further, such α-particle emitting nanoparticles may be coated with gold and functionalized. Additionally, a method for making and using the same are disclosed.